Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Inflation Reduction Act (IRA) boosts biological drugs

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 09, 2024 8:48pm

107 Views

Post# 35924861

RE:RE:RE:RE:RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

As previously posted ...and reinforced by the Ropes & Gray report ..."Single-indication, rare disease assets are unlikely to be subject to IRA price negotiations, and therefore have attracted the interest of dealmakers."

Furthermore, Merck's CEO (MSD and the makers of the the immune checkpoint inhibitor Keytruda) stated earlier this year that MSD's M&A "sweetspot" is US$10 Billion.

<< Previous

Bullboard Posts

Next >>

Twelve Labs partners with AWS to revolutionize video search with AI